We investigated the effects of a diet low in fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs) vs traditional dietary recommendations on health-related quality of life (QOL), anxiety and depression, work productivity, and sleep quality in patients with irritable bowel syndrome and diarrhea (IBS-D).
I rritable bowel syndrome (IBS) is a common gastrointestinal (GI) illness of heterogeneous pathogenesis that is characterized by the presence of characteristic symptoms including abdominal pain and altered bowel habits. 1 Though IBS does not shorten life expectancy or identify patients at increased risk of developing other organic diseases such as colorectal cancer 2 or inflammatory bowel disease, it can profoundly affect the quality of life (QOL) of affected individuals. 3, 4 Further validating the importance of IBS, affected patients consume substantially greater health care resources, undergo more surgical procedures, and have reduced work productivity with higher rates of both absenteeism and presenteeism than do persons without IBS. 5, 6 Based on these facts, it is not surprising that IBS patients account for billions of dollars in direct and indirect health care expenditure each year in the United States.
The reduced QOL reported in IBS patients extends across a wide range of domains as measured by validated generic and disease specific instruments. IBS patients report that their symptoms negatively affect their mood, body image, ability to eat an unrestricted diet, sexual functioning, relationships, and ability to conduct and enjoy their daily activities at work. 3, 8, 9 The decreases in QOL reported by IBS patients are undoubtedly influenced by a number of factors outside of their lower GI symptoms. For example, IBS patients have a substantially increased risk of comorbid functional GI disorders such as functional heartburn and functional dyspepsia, somatic pain conditions such as migraine headache, fibromyalgia, and interstitial cystitis, 10 and psychological distress including anxiety, depression, and somatization. 11 In addition, sleep disorders, which, similar to IBS, are known to exert negative effects on QOL, are reported more commonly in IBS patients than in otherwise healthy persons. 12, 13 The reasons underlying the increased prevalence of GI and non-GI comorbidities in IBS patients remain poorly defined but central and peripheral gut-related mechanisms have been postulated. [14] [15] [16] Up to two-thirds of IBS patients associate symptom onset or exacerbation with eating a meal. 17, 18 Fermentable oligo-, di-, and monosaccharides and polyols (FODMAPs) are poorly absorbed, osmotically active, 19 shortchain carbohydrates that are rapidly fermented by colonic bacteria producing short-chain fatty acids and gases that can trigger symptoms in IBS patients through osmotic effects and luminal distention. 20 We and others have reported improvements in the main symptoms of IBS after dietary FODMAP restriction. [21] [22] [23] [24] However, there are currently little data addressing the effects of the low-FODMAP diet on other aspects of the IBS illness experience including QOL, psychological distress, work productivity, or sleep. 25 We hypothesized that a low-FODMAP diet would improve disease specific QOL, psychological distress, work productivity, and sleep to a greater degree than would standard dietary recommendations for IBS based on modified guidance from the National Institute for Health and Care Excellence (mNICE) in patients with IBS with diarrhea (IBS-D).
Methods
This was a randomized controlled superiority trial with a parallel design conducted in a 1:1 fashion. The primary GI symptom results from this trial are reported elsewhere. 24 In this manuscript, we report results from prespecified secondary endpoints addressing diseasespecific QOL, psychological distress, work productivity, and sleep quality. The protocol was approved by the University of Michigan Hospital and Health Systems Institutional Review Board and registered with ClinicalTrials.gov (NCT01624610). All authors had access to the study data and reviewed and approved the final manuscript.
Patient Population
Adult patients meeting the Rome III criteria for IBS-D 26 (as assessed by a gastroenterologist) were consecutively recruited from the gastroenterology and primary care clinics at the University of Michigan and via local print and online advertising. Inclusion criteria included symptoms compatible with the diagnosis of IBS-D by the Rome III criteria and if relevant, a willingness to maintain a stable dosage of antidepressants during the study. Further inclusion and exclusion criteria are described in the Supplementary Materials.
Study Protocol
Eligible patients were asked to participate in a study that would test the efficacy of 2 diets thought to help IBS symptoms. Instruction regarding the 2 diet interventions was provided by specially trained research dieticians. In the hopes of mimicking real-world conditions, dietitians were not blinded to the study intervention though the investigators analyzing the data were blinded to randomization. After informed consent was obtained, potential subjects entered a 2-week screening period during which IBS symptoms were assessed. Further information about randomization and dietitian education can be found in the Supplementary Materials.
Prespecified Assessments:
Disease-specific QOL, anxiety and depression, activity impairment, and sleep quality were measured before and after the 4-week intervention. We utilized the IBS-QOL questionnaire, the Hospital Anxiety and Depression Scale (HADS), the Work Productivity and Activity Impairment questionnaire, and an 11-point numerical rating scale for sleep quality and fatigue. Further explanation of these instruments and prespecified comparisons can be found in the Supplementary Materials.
Statistical Analysis
The endpoints reported were collected from all patients at baseline and at the end of treatment, but the trial was not powered to detect these changes as this was a secondary analysis. Therefore, the presented analyses are considered to be exploratory in nature. Quantitative data are presented as mean AE SD unless otherwise stated. Baseline comparisons were made using an intention-to-treat analysis (chi-square test and Student t test) for categorical and continuous variables, respectively. Normality of the distribution was demonstrated with a folded F statistic. The 95% confidence intervals (CIs) for categorical outcomes were made by computing confidence limits based on binomial proportions and risk differences within groups. The 95% CIs for continuous variables were computed utilizing Student's t test and paired t test. All patients who were randomized and who received dietary instructions were included in the responder comparisons, where dropouts were considered to be nonresponders (intention-to-treat analysis). For comparisons of questionnaire data at the end of the intervention period vs baseline, only patients who completed the intervention were included (per-protocol analysis). All statistical analyses were performed using SAS (version 9.4, SAS Institute, Cary, NC). Figure 1) . Eighty-four patients completed the study period (45 low FODMAP, 39 mNICE); QOL data were obtained in 88 patients. There were more dropouts in the low-FODMAP arm (5 subjects) than the mNICE arm (2 subjects). Demographics (Table 1 ) and baseline QOL measures (Table 2) were similar between groups, except that there were more obese patients in the mNICE group.
Results

Of
The primary endpoint of adequate relief and other clinical endpoints have been reported previously. 24 Though there were no significant differences in the proportion of those reporting adequate relief (P ¼ .31) or composite endpoint responders (P ¼ .11), the low-FODMAP diet resulted in a significantly higher proportion of abdominal pain responders compared with the mNICE group (51% vs 23%; P ¼ .008). There were similar significantly greater improvements observed in the low-FODMAP group for bloating, consistency, frequency, and urgency than in the mNICE group.
Nutritional Data
Baseline energy, nutrient, and FODMAP intake were similar between groups, but by the end of the 4-week study period, daily ingested total carbohydrates and measurable FODMAPs (fructose, lactose, monosaccharides, polyols) were significantly lower in the low-FODMAP arm compared with the mNICE arm. 24 
Disease-Specific QOL
The mean IBS-QOL score at 4 weeks improved significantly in both groups, but the magnitude of improvement was significantly greater in the low-FODMAP arm compared with the mNICE arm (15.9 vs 5.0 points; 95% CI, -17.4 to -4.3) ( Figure 1A ). In the low-FODMAP arm, significant improvements were observed in all IBS-QOL domains except for food avoidance ( Figure 2 ). Improvements were seen in the mNICE arm as well for several domains (dysphoria, interference with activity, and health worry), but the magnitude of improvement in the low-FODMAP group was significantly greater for the dysphoria, interference with activity, body image, and social reaction domains. Interestingly, food avoidance did not significantly increase or decrease throughout the study for either group. At 4 weeks, the proportion of patients with at least 14-point improvement (meaningful clinical response [MCR]) was greater in the low-FODMAP group compared with the mNICE group (52% vs 21%; 95% CI, -0.52 to -0.08) ( Figure 1B ). The low-FODMAP group reached an MCR for the domains for dysphoria, interference with activity, body image, and social reaction; the mNICE group did not reach MCR for any IBS-QOL domains.
Anxiety and Depression
At 4 weeks, anxiety scores as measured by HADS improved significantly for subjects on the low-FODMAP diet (9.13 to 7.73; 95% CI, -2.10 to -0.59), whereas anxiety in the mNICE group did not change significantly (9.31 to 9.54; 95% CI, -0.64, 1.10) ( Figure 3A ). The between-group difference in the magnitude of improvement in anxiety scores was also statistically significant (1.63; 95% CI, 0.46-2.80). The proportion of patients with anxiety scores ( 8) was not significantly different between the low-FODMAP group and mNICE arms (52%; 95% CI, 0.37-0.68 vs 37%; 95% CI, 0.21-0.53). Depression scores improved in both groups compared with baseline, but were only significantly improved in the low-FODMAP arm ( Figure 3B ). The between-group difference in the magnitude of improvement in depression scores was not statistically significant (95% CI, -0.70 to -1.30). The proportion of patients with depression scores 8 was similar in the low-FODMAP group compared with the mNICE group (85%; 95% CI, 0.67-0.93 vs 80%; 95% CI, 0.73-0.96).
Work Productivity and Activity Impairment
Work Productivity and Activity Impairment scores collected at baseline and after the 4-week intervention demonstrated no significant improvement in absenteeism, presenteeism, or work productivity with either the low-FODMAP or mNICE diets (Table 3) . However, whereas activity impairment scores at 4 weeks compared with baseline improved with both diet interventions, the magnitude of benefit reported by the low-FODMAP group was significantly greater than that reported by the mNICE group (13.50; 95% CI [2.72, 24.20) (Table 4) .
Sleep and Fatigue
Compared with baseline, the mean sleep and fatigue scores at 4 weeks for the low-FODMAP group improved significantly, though the magnitude of change between the 2 groups was not statistically significantly different (95% CI, -0.29 to 1.20; 95% CI, -0.46 to 1.13, respectively) (Table 5) . For sleep quality as measured by the modified sleep questionnaire, the low-FODMAP diet but not the mNICE diet group experienced improvements in overall sleep quality (95% CI, -1.62 to -0.10; daytime fatigue; 95% CI, -0.56 to -0.07) and trouble falling asleep (95% CI, -0.65 to -0.03) at 4 weeks when compared with baseline. However, the difference between the two treatment groups was not significantly different (95% CI, -0.17 to 1.58; 95% CI, -0.09 to 0.61; 95% CI, -0.09 to 0.67).
Correlations
No correlation was detected between symptom response to dietary intervention (as measured by improvement in abdominal pain or by reporting of adequate relief of IBS symptoms) and improvement in QOL, psychological indices, or baseline antidepressant use.
Discussion
In this post hoc analysis of prespecified secondary outcomes, we found that the low-FODMAP diet led to significant improvements in QOL, anxiety, and activity impairment compared with a diet intervention based on mNICE guidelines. This work extends the benefits of the low-FODMAP diet beyond improving specific GI symptoms to more patient-centered outcomes.
Given that IBS is a symptom-based diagnosis, clinical trials have tended to focus on the ability of an intervention to improve the cardinal GI symptoms of IBS. Although improving GI symptoms is certainly important to IBS patients, focusing only on GI symptoms may fail to recognize the true impact of IBS on patient's daily lives and ability to function. In addition, it is clear that the illness experience of many IBS patients extends beyond their GI symptoms to include mental health issues 27 and sleep. 28 For these reasons, studies which take a holistic view of the impact of an intervention on Difference of the change in the average score from baseline at week 4 for low FODMAP and mNICE subjects. Difference of the change in the average score from baseline at week 4 for low FODMAP and mNICE subjects.
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Patients randomized to the low-FODMAP diet were more than twice as likely to experience an MCR. Furthermore, those randomized to the low-FODMAP diet reached the threshold for an MCR for dysphoria, interference with activity, body image, and social reaction, whereas the MNICE group did not achieve an MCR for any individual IBS-QOL domains. These data demonstrate a profound effect of the low-FODMAP diet on IBS-specific QOL. We found the lack of effect of the low-FODMAP diet on food avoidance scores to be particularly interesting. The low-FODMAP diet is widely regarded to be highly restrictive and difficult for patients to adhere to, dissuading many from even attempting it. Our data, along with that from others, 30 suggest that the low-FODMAP diet may not be as burdensome to IBS-D patients as is widely perceived and is no more burdensome than traditional dietary advice offered to IBS patients.
There are very little other data addressing the impact of the low-FODMAP diet on QOL in IBS patients. In an unblinded, controlled trial of IBS patients from Denmark 31 who were randomized to the low-FODMAP diet (n ¼ 42), a Lactobacillus rhamnosus GG probiotic (n ¼ 41), or a usual Danish diet (n ¼ 40), there were no statistically significant between-group differences in IBS-QOL scores at the end of the intervention period. However, significant improvements in IBS-QOL scores compared with baseline were observed with the low FODAMP diet but not the probiotic or usual Danish diet. The reasons for the differences in results between our study and the Danish study are not clear but might be attributable to differences in study populations (eg, our patient population was older [42 years of age] than were patients in the Danish study [37 years of age]), dietary habits between Denmark and the United States, or differences in study protocols.
There are increasing data to support a link between food, the microbiome, and mood. [32] [33] [34] In our study, the low-FODMAP diet led to statistically significant decreases in anxiety and depression scores at 4 weeks whereas there was no statistically significant improvement for the mNICE group. One issue that we cannot address in our study is whether anxiety state or trait improved. HADS is unable to distinguish between these 2 conditions and it is possible that although anxiety was improved by the low-FODMAP diet, patients could still have experienced anxiety, albeit to a lesser degree. Similar improvement in HADS scores (but not state anxiety or depression) were observed with a low- FODMAP diet and gut-directed hypnotherapy in a recently published Australian study. 30 The mechanism(s) which underlie these observations are unclear, though one could plausibly suggest "top-down" or "bottom-up" models. It is entirely possible that by improving GI symptoms, patients felt less anxious about eating a meal. On the other hand, recent data have drawn a link between psychosocial distress, altered central processing, and modulation of nutrient-related visceral sensory signals. 30 Higher levels of psychiatric comorbidity are associated with higher preprandial and postprandial GI symptom burden in IBS patients. 14 Restriction of FODMAPs may improve psychiatric comorbidity, 35 through modulation of the gut microbiome or mucosal immune system. 36 Further studies to understand this interesting observation are warranted.
Decreases in work productivity and activity impairment are common in IBS and exact a significant toll on patients and society. Few IBS treatments have demonstrated benefits for these important outcomes. 37 The low-FODMAP diet led to a statistically significant improvement in absenteeism and presenteeism at 4 weeks when compared with baseline. However, between-group differences for absenteeism and presenteeism were not statistically significant. Though the low-FODMAP diet and the mNICE diet both led to statistically significant improvements in activity impairment at 4 weeks when compared with baseline, the magnitude of benefit with the low-FODMAP diet was significantly greater than the mNICE diet. This finding is consistent with the significant decrease in interference with activity subscale scores found on the IBS-QOL with the low-FODMAP diet vs the mNICE diet. Ours is the first study to show such robust benefits in activity impairment and validates the important downstream consequences of the low-FODMAP diet to patients with IBS-D.
Sleep disturbances are common in IBS patients and may well contribute to reductions in QOL, work productivity, and activity impairment. 12, 13 In a preliminary assessment utilizing selected questions from the validated Sleep-50 Questionnaire, we found that the low-FODMAP diet improved overall sleep quality and fatigue at 4 weeks when compared with baseline. However, between group differences were not significantly different.
Our study has several important limitations. Although our endpoints were prespecified, the study was not powered for these secondary endpoints; thus, type II errors may have occurred and thus, our study should be viewed as more of an exploratory than definitive work. Also, the improvement noted in psychologic indices and disease specific QOL were measured at 4 weeks only, and may not necessarily translate into long term improvement (although longterm benefit for these endpoints has been noted in other studies). 30 Given that meals were not supplied to subjects, complete blinding was not possible, and bias might have been interjected by the dietitians or patients. Though awareness of the low-FODMAP diet has increased over time, it was relatively unrecognized in Michigan during the time this trial was conducted. In addition, rather than utilizing our clinical GI dieticians for this trial, we utilized a separate group of fully trained research dieticians to instruct study participants on the diet interventions in the hopes of reducing the likelihood of introducing bias toward one intervention or the other. We were careful to have the dieticians tell patients that they were to be randomized to 1 of 2 diet therapies for IBS (diet 1 or diet 2) and to avoid any discussion of efficacy or research conducted regarding either intervention. The short duration of the diet intervention could be viewed as a study limitation. However, the 4 week diet intervention period was chosen to reflect how the full FODMAP elimination phase is intended to be used in clinical practice, It should be remembered that the low-FODMAP diet plan consists of 3 separate stages: an elimination phase during which all FODMAPs are eliminated in the hopes of identifying IBS patients who are sensitive to FODMAPs, a reintroduction phase in which responders to the elimination phase undergo a structured reintroduction of foods containing individual FODMAPs in the hopes of identifying their specific triggers, and a maintenance phase in which information from the reintroduction phase is used to liberalize and tailor the diet thus creating each individual IBS patient's maintenance diet. Our study demonstrated benefits of the FODMAP elimination phase, which is only intended for short-term use, to symptoms and QOL in IBS-D patients. Subsequent studies will be required to better understand the reintroduction and maintenance phases of the low-FODMAP diet plan. Finally, although there was a significantly higher average body mass index (BMI) in the mNICE group, there were no significant differences between the groups in categorical BMI. Although there are no data to suggest that obese patients with IBS would respond differently to the 2 dietary interventions, it is possible that this imbalance could have introduced unintended bias. It is worth noting that there was no difference in response to either intervention between obese (BMI !30 kg/m 2 ) and nonobese patients (BMI <30 kg/m 2 ), acknowledging that our study was not designed or powered to adequately address this question.
In this US randomized, controlled trial, the low-FODMAP diet vs the mNICE diet demonstrated significant benefits for QOL, anxiety, and activity impairment in patients with IBS-D. This study is one of the first to extend the benefits of the low-FODMAP diet beyond improving GI symptoms in IBS patients, and, will hopefully prompt further investigation investigating the relationship of diet, GI symptoms, and QOL. When benefits for these important patient-centered outcomes are combined with the improvements in GI symptoms reported by our group and others, it is logical to conclude that the low-FODMAP diet is an effective treatment intervention for patients with IBS-D.
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Supplementary Information Patient Population
Documentation of a normal colonoscopy or flexible sigmoidoscopy with normal colonic mucosal biopsies within 5 years as well as normal complete blood count, electrolyte panel, thyroid stimulating hormone, and a negative evaluation for celiac disease (tissue transglutaminase IgA, endomysial antibody, or duodenal biopsy) were also necessary to be eligible. Exclusion criteria included symptoms compatible with irritable bowel syndrome (IBS) with mixed or constipation subtype, comorbid medical problems affecting gastrointestinal transit/motility (eg, scleroderma, poorly controlled diabetes), inflammatory bowel disease, severe renal or hepatic disease, previous abdominal surgery (other than appendectomy, cholecystectomy [if <6 months prior to enrollment], and gynecologic or urologic surgery), and previous treatment with a low fermentable oligo-, di-, and monosaccharaides and polyols (FODMAP) diet. Pregnant patients and those currently taking probiotics, antibiotics, or narcotics were also excluded. Active participation in another form of dietary therapy at the time of enrollment (ie, gluten free, low carbohydrate, and high protein) was not allowed.
Methods
To be eligible for randomization, both an average daily abdominal pain score of 4 or higher on an 11-point numerical rating scale (0 ¼ no pain, 10 ¼ intolerable pain) and an average daily stool consistency, assessed by the Bristol Stool Form Scale, of !5 were required. IBS with diarrhea patients who fulfilled the entry criteria were randomized via computer generation in a 1:1 ratio to a low-FODMAP diet or modified diet recommended by the National Institute for Health and Care Excellence (mNICE) guidelines for IBS.
Randomized patients met with a trained research dietitian at the Michigan Clinical Research Unit and were counseled on their allocated diet. Patients were informed that they were going to be randomized to 1 of 2 dietary interventions for patients with IBS with diarrhea: diet 1 or diet 2. Using standardized instructions, the mNICE group was instructed to eat small frequent meals, avoid trigger foods, and avoid excess alcohol and caffeine. Foods containing FODMAPs were not specifically excluded as part of the mNICE instructions provided to study participants. For the low-FODMAP diet, instruction was administered in a standardized manner according to published materials from Monash University 1 but subjects were given teaching materials created from the University of Michigan. Dietary compliance measures used in the counseling environment included prospectively recorded 3-day food diaries. Food diaries were analyzed via the Nutrition Data System for Research computer program, measuring fructose, lactose, sucrose, pectins, sorbitol, and added sugars. At the completion of week 2, a second visit was conducted to answer questions, assess adverse events, and obtain information regarding dietary intake. At the completion of the 4-week study period, subjects met with the research dietitian to collect and assess the prospectively recorded 3-day food diaries and 24-hour dietary recall along with collection of quality-of-life (QOL) endpoints.
Prespecified Endpoints
The IBS-QOL questionnaire is a validated conditionspecific quality-of-life measure for IBS with established internal consistency and reproducibility. [2] [3] [4] The IBS-QOL contains 41 descriptive IBS-specific quality of life items and uses a 5-point Likert-type response scale. A higher score on this scale correlates with a better QOL. Meaningful clinical improvement is seen by a change in IBS-QOL score >10-14.
3 This questionnaire was administered before and after the 4-week intervention. Improvements in mean scores, change in score, and proportion of subjects reporting 10-and 14-point improvement were compared between the 2 interventions.
Anxiety and Depression
To measure participants' anxiety and depression, the Hospital Anxiety and Depression Scale was used at baseline and at week 4. 5 The Hospital Anxiety and Depression Scale is a self-reported rating scale of 14 items used to identify and quantify depression and anxiety (7 items for each subscale). It is considered an effective screening measure for anxiety and depression and has been widely used. 6, 7 It has 2 subscales, which evaluate anxiety and depression, with a higher score indicating more severe symptoms. The scores for each subscale range from 0 to 21; a cutoff score of 8 was used for each subscale. The proportion of patients reporting a score 8 or lower was compared between the 2 groups, as was the change in mean score from baseline.
Work Productivity and Activity Impairment
Health-related work productivity loss includes time lost from work (absenteeism) and reduced on-the-job effectiveness (presenteeism). The Work Productivity and Activity Impairment questionnaire measures work time missed and work and activity impairment because of a specified health problem during the past 7 days. 8 The Work Productivity and Activity Impairment IBS questionnaire consists of 6 questions and results in an overall work impairment (productivity loss) score, with higher scores indicating greater impairment.
Derived from the questionnaire are 4 metrics: absenteeism (the percentage of work time missed due to health in the past 7 days), presenteeism (the percentage of impairment suffered while at work due to health in the past 7 days), overall work impairment (the total percentage of missed time due to absenteeism or presenteeism in the past 7 days), and activity impairment (the percentage of impairment suffered during daily activities in the past 7 days). Each metric varies from 0% to 100%, with higher scores indicating greater impairment. Only respondents currently employed (full-time, parttime, or self-employed) provide information on absenteeism, presenteeism, and overall work impairment (as one must be employed for health to affect work productivity). All respondents provide information on activity impairment. Both between-group and withingroup scores were compared before and after dietary intervention.
Sleep and Fatigue
Sleep and fatigue were measured daily during the baseline and study period via an 11-point numerical rating system (0 ¼ best, 10 ¼ worst). In addition, 3 items from the modified Sleep-50 questionnaire were used to assess overall sleep quality ("Generally, I sleep badly," "I feel sleepy during the day and struggle to remain alert," and "I have difficulty falling asleep"), and was administered before and after the 4-week dietary intervention and scored from 0 to 3 (3 being the worst). The Sleep-50 questionnaire is designed to screen for multiple sleep disorders over the prior 4 weeks.
